Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. The Company’s lead product candidate, LX-101, is a novel, clinical-stage, precision-engineered targeted therapy directed to the insulin-like growth factor-1 (IGF-1) receptor (IGF-1R). The IGF-1/IGF-1R pathway is implicated in a host of malignancies and autoimmune diseases. LX-101 consists of an optimized, precision-engineered IGF-1 variant, with high affinity to IGF-1R and reduced affinity to IGF binding proteins (IGFBPs), coupled to the cytotoxic payload, methotrexate. Methotrexate is a cytotoxic inhibitor of DNA synthesis, repair, and cellular replication and is used to treat patients with certain cancers and autoimmune diseases, including TED.